Asenapine, a novel psychopharmacologic agent: Preclinical evidence for clinical effects in schizophrenia

Psychopharmacology

Volumn 196, Issue 3, 2008, Pages 417-429

  Frånberg, Olivia ^a   Wiker, Charlotte ^a   Marcus, Monica M ^a   Konradsson, Åsa ^a   Jardemark, Kent ^a   Schilström, Björn ^a   Shahid, Mohammed ^b   Wong, Erik H F ^c   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PFIZER INC   (United States)

Author keywords

Asenapine; CAR; Catalepsy; Dopamine; Electrophysiology; Glutamate; Microdialysis; Rat; Schizophrenia; Voltammetry

Indexed keywords

ASENAPINE; CLOZAPINE; DOPAMINE; N METHYL DEXTRO ASPARTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTROPHYSIOLOGY; EXTRAPYRAMIDAL SYMPTOM; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; POTENTIOMETRY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SYMPTOM;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; CATALEPSY; CONDITIONING, CLASSICAL; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; INJECTIONS, SUBCUTANEOUS; MALE; MICRODIALYSIS; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; RATS; RATS, WISTAR; SCHIZOPHRENIA;

EID: 38849164363     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0973-y     Document Type: Article

References (68)

1. Ahlenius S, Hillegaart V (1986) Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission. Pharmacol Biochem Behav 24:1409-1415
2. 2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-d-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 18:197-209
3. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY (1997) Clozapine and haloperidol modulate N-methyl-d-aspartate- and non-N-methyl-d-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283:226-234
4. Broekkamp CL, De Graaf JS, van Delft AM (1990) Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino-[4,5- c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors. Arzneimittelforschung 40(5):544-549
5. Carlsson A (1978) Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 135:165-173
6. 1 receptor stimulation. Science 287:2020-2022
7. Chen L, Yang CR (2002) Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J Neurophysiol 87:2324-2336
8. Costall B, Domeney AM, Kelly ME, Naylor RJ, Tomkins DM (1990) Actions of ORG 5222 as a novel psychotropic agent. Pharmacol Biochem Behav 35(3):607-615
9. Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553-564
10. Deutch AY (1993) Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. J Neural Transm Gen Sect 91:197-221
11. Deutch AY, Cameron DS (1992) Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience 46:49-56
12. Deutch AY, Lee MC, Iadarola MJ (1992) Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: The nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 46:49-56
13. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98:6917-6922
14. Eltayb A, Wadenberg ML, Svensson TH (2005) Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose l-dopa. Biol Psychiatry 58:337-343
15. Emamian ES, Karayiorgou M, Gogos JA (2004) Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with Schizophrenia. J Neurosci 24:1561-1564
16. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76
17. 1 receptor antagonist. Lancet 6;337(8745):854-855
18. Goldman-Rakic PS, Muly EC, Williams GV (2000) D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 31:295-301
19. Gonon FG (1988) Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 24:19-28
20. Gonon F, Buda M, Pujol JF (1984) Treated carbon fibre electrodes for measuring catechols and ascorbic acid. In: Marsden CA (ed) Measurement of neurotransmittor release in vivo. Wiley, Chichester, UK, pp 153-171
21. Hertel P, Nomikos GG, Iurlo M, Svensson TH (1996) Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (Berl) 124:74-86
22. Hertel P, Fagerquist MV, Svensson TH (1999) Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 286:105-107
23. Hoffman DC, Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120(2):128-133
24. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225
25. 3 receptor antagonists as therapeutic agents. Drug Discov Today 10:917-925
26. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
27. Karlsson P, Smith L, Farde L, Härnryd C, Sedvall G, Wiesel F-A (1995) Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology 121:309-316
28. Konradsson A, Marcus MM, Hertel P, Svensson TH, Jardemark KE (2006) Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex. Synapse 60:102-108
29. Kuroki T, Meltzer HY, Ichikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774-781
30. Li C (1964) Introduction to experimental statistics. McGraw-Hill, New York, USA, pp 207-226
31. Liégeois JF, Ichikawa J, Meltzer HY (2002) 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 947:157-165
32. Litman RE, Su TP, Potter WZ, Hong WW, Pickar D (1996) Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 168:571-579
33. Marcus MM, Nomikos GG, Svensson TH (1996) Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur Neuropsychopharmacol 6:29-38
34. Marcus MM, Nomikos GG, Svensson TH (2000) Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism. Eur Neuropsychopharmacol 10:245-253
35. Marcus MM, Malmerfelt A, Nyberg S, Svensson TH (2002) Biochemical effects in brain of low doses of haloperidol are qualitatively similar to those of high doses. Eur Neuropsychopharmacol 12:379-386
36. 2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol 8:315-327
37. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255
38. Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755-1760
39. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98:427-436
40. Ninan I, Wang RY (2003) Modulation of the ability of clozapine to facilitate NMDA- and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: pharmacological evidence. Eur J Neurosci 17:1306-1312
41. Ninan I, Jardemark KE, Wang RY (2003) Differential effects of atypical and typical antipsychotic drugs on N-methyl-d-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 48:66-79
42. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology (Berl) 115:147-156
43. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152:1444-1449
44. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic, New York, USA
45. Potkin SG, Fleming K, Binneman B, Keller DS, Alphs L, Panagides J (2006) Asenapine effects on cognitive function during acute episodes of schizophrenia: a randomized placebo- and risperidone-controlled trial. Neuropsychopharmacology 31:251
46. Potkin SG, Cohen M, Panagides J (2007) Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry (in press)
47. Robertson GS, Fibiger HC (1992) Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46(2):315-328
48. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403-1410
49. Salmi P, Samuelsson J, Ahlenius S (1994) A new computer-assisted two-way avoidance conditioning equipment for rats: behavioral and pharmacological validation. J Pharmacol Toxicol Methods 32:155-159
50. Schilström B, Nomikos GG, Nisell M, Hertel P, Svensson TH (1998) N-methyl-d-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82:781-789
51. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57-73
52. Sedvall G, Farde L (1995) Chemical brain anatomy in schizophrenia. Lancet 346:743-749
53. Shahid M, Summer BEH, Wong EHF, Henry B (2007a) Asenapine displays distinctive induction patterns of c-fos mRNA expression in rat forebrain regions. Biol Psychiatry 61(8):256S-256S 826 Suppl. 2
54. Shahid M, Walker GB, Zorn SH, Wong EHF (2007b) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol (in press)
55. Siegel S, Castellan JNJ (1988) Nonparametric statistics for the behavioral sciences. McGraw-Hill, New York, USA
56. 3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5:25-43
57. Svensson TH (2003a) Preclinical effects of conventional and atypical antipsychotic drugs: defining the mechanisms of action. Clinical Neuroscience Research 3:34-36
58. Svensson TH (2003b) Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1145-1158
59. Tandon R (2002) Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q 73:297-311
60. 7 receptors. Curr Drug Targets CNS Neurol Disord 3(1):81-90
61. Wadenberg ML, Ahlenius S, Svensson TH (1993) Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: implications for the mechanism of action of clozapine. Psychopharmacology (Berl) 110:273-279
62. Wadenberg ML, Hicks PB (1999) The conditioned avoidance response test re evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851-862
63. 2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150:422-429
64. Wadenberg MG, Browning JL, Young KA, Hicks PB (2001a) Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacol Biochem Behav 68:363-370
65. Wadenberg ML, Soliman A, VanderSpek SC, Kapur S (2001b) Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25:633-641
66. Wadenberg ML, Wiker C, Svensson TH (2007) Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha 2 adrenoceptor blockade: experimental evidence. Int J Neuropsychopharmacol 10(2):191-202
67. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, Berman KF, Goldberg TE (2001) Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50:825-844
68. 6 receptors. Curr Drug Targets CNS Neurol Disord 3(1):59-79